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Colorectal cancer (CRC) is a very common malignancy that has become one of the leading causes of morbidity and death worldwide. Although there have been advances in surgical and chemotherapeutic treatments of CRC, overall patient survival has not significantly improved in recent years. The potential anticancer activities of DNA methyltransferase inhibitors (MTIs) have emerged as promising chemotherapeutic or preventive agents and therefore have undergone extensive study. Based on promising in vivo antitumour activity demonstrated by 5-aza-2Ј-deoxycytidine (5-aza-dc) in preclinical studies, the Food and Drug Administration approved 5-aza-dc for clinical evaluation for its ability to treat myelodysplastic syndromes and chronic myelomonocytic leukaemia
. Zebularine is another MTI that has been shown to demonstrate significant anti-proliferative effects against ovarian cancer cell lines; it appears to be a promising clinical candidate for the therapy of drug-resistant ovarian cancer [8] . [9] . During the past few years, accumulating evidence has also identified consequences of dysregulation of JAK/STAT signalling, particularly in regard to JAK2/STAT3/STAT5 signalling that has been shown to have roles in the oncogenesis of several cell types [10] [11] [12] [13] [14] . In CRC cells, constitutive activation of JAK/STAT signalling has been shown to contribute to the initiation and progression of CRC tumorigenesis through the up-regulation of a number of proteins that mediate anti-apoptotic effects or cell cycle progression [15] [16] [17] [18] [19] [20] [21] . [9, 20, [22] [23] [24] [25] . Based on experiments that show restoration of SHP1 or SOCSs expression suppresses cancer cell growth [19, 24, 26] , SHP1, SOCS1 and SOCS3 have been reported to have tumour suppressor functions [25] [26] [27] [28] [29] . Previous studies have also suggested that SHP1 and SOCSs are silenced by aberrant methylation of their CpG islands. For example, Chim and coworkers detected hypermethylation in SOCS1 and SHP1 in multiple myeloma [20] , and SOCS3 hypermethylation was reported in human lung cancer [24] . These data suggest that demethylating agents may be useful in the treatment of cancer [19, 23] .
Signalling from Janus kinase (JAK) and signal transducers and activators of transcription (STAT) proteins have been shown to play a significant role in various biological effects, including immune function, cell growth, differentiation and hematopoiesis
. Based on these roles for JAK/STAT signalling, it is suggested that targeting JAK/STAT proteins may represent a valuable therapeutic strategy for cancer therapy. Proteins that regulate JAK/STAT signalling may also have a role. The SH2-containing protein tyrosine phosphatase 1 (SHP1) protein and the suppressors of cytokine signalling (SOCS) family of proteins have been identified as important negative regulators in cytokine-mediated signal transduction as well in the JAK/STAT signalling pathway
Correspondingly, it is has been suggested that loss of SHP1 or SOCSs may contribute to the activation of JAK or STAT proteins in cancer
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Materials and methods
Cell culture and pharmacologic agents
Cell viability assays
Cell viability was assessed using a tetrazolium salt (WST-8)-based colorimetric assay provided by the Cell Counting Kit 8 (CCK-8, Dojindo
, Japan) [32, 33] 
Detection of apoptosis
In vitro invasion assays
Cell invasion assays were performed as described by Hecht et al. [34] . (Fig. 2A) . For the 10 sequenced clones, the proportion of methylated residues detected ranged from 18.2% (2/11) to 100% (11/11) (Fig. 2B) . In contrast, no significant changes in methylation status of the SOCS1 and SOCS3 promoters were detected (Fig. 2B) . These findings provide a correlation between hypermethylation of the SHP1 promoter and changes in SHP1 expression in CRC cells. 
Briefly, 8-m-pored polycarbonate membranes were coated with Matrigel
SHP1 expression induces down-regulation of JAK2/STAT3/STAT5 pathways
SHP1 decreases JAK2 expression via the proteasome pathway in CRC cells
To determine whether the proteasome pathway has a role in SHP1-mediated degradation of JAK2, CRC cells were treated with Fig. 6A 
Fig. 4 5-aza-dc induces down-regulation of JAK2/STAT3/STAT5 protein levels. (A) Western blot analysis revealed decreases in JAK2 and pJAK2 protein levels for SW1116 cells treated with 5-aza-dc. In the same experiment, decreases in STAT3, pSTAT3 and pSTAT5 were also identified. The data shown are from a representative experiment and detection of GAPDH was used as a loading control. (B) Quantitative real-time PCR analysis of JAK2, STAT3 and STAT5 in SW1116 cells treated with 5-aza-dc. Results are expressed as relative expression compared to untreated cells. Each value is the mean Ϯ S.D. of three experiments.
M MG132, a pharmacological proteasome inhibitor, 48 hrs after transfection with pEGFP-N1-SHP1 and cell sorting for the GFP-positive cell population. As shown in Fig. 5, the basal level of JAK2 in pEGFP-N1-SHP1 transfected SW1116 cells was much lower than that in pEGFP-N1 transfected cells. However, after hrs in the presence of M MG132, the level of JAK2 protein was approximately equal between the pEGFP-N1-SHP1-and pEGFP-N1-transfected cells. A similar protein expression pattern was seen in HT29 cells, indicating that MG132 can prevent SHP1-mediated down-regulation of JAK2 through the proteasome pathway.
Disruption of JAK2/STAT3/STAT5 signalling by 5-aza-dc is associated with modulation of some JAK2/STAT3/STAT5 downstream targets
To test if alterations in the JAK2/STAT3/STAT5 pathway by 5-aza-dc lead to significant changes in downstream targets, we examined the expression of various proteins involved in apoptosis, cell cycle progression, invasion and migration. As illustrated in
5-aza-dc suppresses CRC cell growth and induces G2 cell cycle arrest and apoptosis without affecting cell invasion
Using a CCK-8 assay (Fig. 7A) (Fig. 7C), corresponding to a 3.80-and  3 .12-fold increase in apoptosis for the SW1116 and HT29 cell lines, respectively. In addition, as shown in Fig. 7D , pretreatment of CRC cells with 5 M 5-aza-dc for 96 hrs stimulated cleavage of caspase-3, suggesting that caspase-3 activation may play a significant role in 5-aza-dc induced apoptosis. Cell invasion assays were also performed, and no significant inhibition of invasion was observed following cell treatment with 5-aza-dc (Fig. 7E ).
Fig. 7 Biological effects of 5-aza-dc in CRC cells. (A) CCK-8 assay of CRC cells treated with 5 M 5-aza-dc or solvent only as a negative control. The cell numbers of 5-aza-dc-treated cells were normalized to that of the negative control and showed a concentration-and time-dependent decrease in the number of viable CRC cells treated with 5-aza-dc compared to negative control cells (*P Ͻ 0.05). (B) Cell cycle analysis was performed 72 hrs after CRC cells were treated with diluent (left) or 5-aza-dc (5 M, right). Compared to negative control cells, treated cells showed an increased proportion of cells in the G2 phase. Data shown are from a representative experiment. (C) CRC cells were treated with diluent (left) or 5-aza-dc (5 M, right) for 96 hrs and then analysed for the presence of cell apoptosis by flow cytometric analysis. A 3.80-and 3.12-fold increase in apoptotic cells were detected for SW1116 and HT29 cells treated with 5 M 5-aza-dc relative to control cells. The data shown are from a representative experiment. (D) Cleavage of caspase-3 in CRC cells treated with 5 M 5-aza-dc was detected 96 hrs after treatment. Each value is the mean Ϯ S.D. of three experiments (*P Ͻ 0.05). (E) An in vitro cell invasion assay was performed using SW1116 cells as described in the '
Discussion
Hypermethylation of promoters of various tumour suppressor genes causes their transcriptional silencing. However, hypomethylation of regulatory DNA sequences activates transcription of protooncogenes, retrotransposons, as well as genes encoding proteins involved in genomic instability and malignant cell metastasis.
The mechanism of transcriptional repression via DNA methylation suggests that DNA methylation directly inhibits the binding of transcription factors to their binding sites within a promoter sequence [35] . 5-aza-dc treatment has been shown to open the chromosomal region to increase accessibility for transcription factor complexes to assemble at the promoter and drive gene transcription. Therefore, 5-aza-dc has been characterized as a demethylation agent that can re-induce expression of TSGs [36] . Although 5-aza-dc has been reported as a promising therapeutic agent for myelodysplastic syndromes and chronic myelomonocytic leukaemia, the mechanisms underlying the role of MTIs in cancer therapy are poorly understood. In addition to a role in DNA demethylation, 5-aza-dc has also been shown to mediate anticancer effects through DNA damage [37, 38] [40] . We further suggest that the lack of significant change in STAT5 levels in response to SHP1 upregulation is the result of STAT5 regulation by other pathways involving Src kinase [41] . (Fig. 8) . Therefore, further study of 5-aza-dc on JAK2/STAT3/STAT5 signalling in CRC tumorigenesis and progression has the potential to advance the development of effective agents for CRC prevention and therapy. Additionally, since 5-azadc also affects mRNA stability, further studies regarding this effect should be performed. 
